PPARγ mediates the anti-pulmonary fibrosis effect of icaritin

• Published in: Toxicology letters 2021-10, Vol.350, p.81-90
• Main Authors: Hua, Qingzhong, Huang, Xiaoting, Xie, Weixi, Zhao, Feiyan, Cheng, Haipeng, Luo, Ziqiang, Han, Jianzhong, Wang, Zun, Zeng, Qian, Lin, Miao, Zhou, Tingting, Zhang, Jialu, Gu, Can, Liu, Wei, Tang, Siyuan
• Format: Article
• Language: English
• Subjects: Bleomycin; Icaritin; Myofibroblast; Peroxisome proliferator-activated receptor gamma; Pulmonary fibrosis
• ISSN: 0378-4274; 1879-3169
• DOI: 10.1016/j.toxlet.2021.06.014

[Display omitted] •Icaritin had beneficial effect in alleviating bleomycin-induced pulmonary fibrosis in mice.•Icaritin showed modulation ability on fibrosis indicators (α-SMA, Collagen I).•Icaritin inhibited TGF-β-induced myofibroblast differentiation in NIH3T3 cells and HLF-1 cells.•PPARγ antagonist GW9662 and PPARγ-targeted siRNA reduced the effect of icaritin on myofibroblast differentiation. Pulmonary fibrosis is a fatal lung disease with limited treatment options. Icaritin is the active ingredient derived from the traditional Chinese medical plant Epimedium and possesses many biomedical activities. This study aimed to investigate the effects and molecular mechanisms of icaritin on bleomycin-induced pulmonary fibrosis in mice. To assess its preventative effects, bleomycin treated mice received 0, 0.04, 0.2, and 1 mg/kg of icaritin from day 1 onwards. To assess its therapeutic effects, bleomycin treated mice received 0 and 1 mg/kg of icaritin from day 15 onwards. Mice were sacrificed on day 21 and lung tissues were collected, stained with HE, Masson and immunohistochemistry. Q-PCR was used to measure Collagen I and Collagen III expression, western blotting was used to quantify α-SMA, Collagen I expression. Hydroxyproline content was measured using a biochemical method. NIH3T3 and HLF-1 cells were treated with TGF-β1with or without icaritin, and α-SMA, Collagen I were tested. PPARγ antagonist GW9662 and PPARγ-targeted siRNA were used to investigate the mechanism of icaritin in inhibiting myofibroblast differentiation. Both preventative and therapeutic administration of icaritin improved the histopathological changes, decreased Collagen and α-SMA, lowered hydroxyproline content in bleomycin-treated lung tissues. Icaritin decreased α-SMA and Collagen I expression in TGF-β1-stimulated NIH3T3 and HLF-1 cells. However, its effect in reducing α-SMA and Collagen I expression was suppressed when expression or activity of PPARγ was inhibited. Icaritin has therapeutic potential against pulmonary fibrosis via the inhibition of myofibroblast differentiation, which may be mediated by PPARγ.